Company news

Senti Biosciences Holdings, Inc. news in 2023

Senti Biosciences Holdings, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

December 21, 2023

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

November 12, 2023

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

November 5, 2023

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

October 30, 2023

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

September 26, 2023

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 10, 2023

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

August 9, 2023

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

May 8, 2023

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

May 1, 2023

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

March 21, 2023

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

March 13, 2023

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

January 26, 2023

Decks in 2023